Rate of neurotoxicant exposure determines morphologic manifestations of distal axonopathy

被引:35
作者
LoPachin, RM
Lehning, EJ
Opanashuk, LA
Jortner, BS
机构
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Anesthesiol, Bronx, NY 10467 USA
[2] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Blacksburg, VA 24061 USA
关键词
D O I
10.1006/taap.2000.8984
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Exposure to a variety of agricultural, industrial, and pharmaceutical chemicals produces nerve damage classified as a central-peripheral distal axonopathy. Morphologically, this axonopathy is characterized by distal axon swellings and secondary degeneration. Over the past 25 years substantial research efforts have been devoted toward deciphering the molecular mechanisms of these presumed hallmark neuropathic features. However, recent studies suggest that axon swelling and degeneration are related to sub-chronic low-dose neurotoxicant exposure rates (i.e., mg toxicant/ kg/day) and not to the development of neurophysiological deficits or behavioral toxicity. This suggests these phenomena are nonspecific and of uncertain pathophysiologic relevance. This possibility has significant implications for research investigating mechanisms of neurotoxicity, development of exposure biomarkers, design of risk assessment models, neurotoxicant classification schemes, and clinical diagnosis and treatment of toxic neuropathies. In this commentary we will review the evidence for the dose-related dependency of distal axonopathies and discuss how this concept might influence our current understanding of chemical-induced neurotoxicities. (C) 2000 Academic Press.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 83 条
[1]   NEUROTOXICITY OF GLYCIDAMIDE, AN ACRYLAMIDE METABOLITE, FOLLOWING INTRAPERITONEAL INJECTIONS IN RATS [J].
ABOUDONIA, MB ;
IBRAHIM, SM ;
CORCORAN, JJ ;
LACK, L ;
FRIEDMAN, MA ;
LAPADULA, DM .
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, 1993, 39 (04) :447-464
[2]  
[Anonymous], EXPT CLIN NEUROTOXIC
[3]  
ANTHONY DC, 1983, TOXICOL APPL PHARM, V71, P362
[4]  
BARBER D, 2000, TOXICOLOGIST, V54, P177
[5]  
Berger Alan R., 1995, P648
[6]   FORMATION OF HEMOGLOBIN ADDUCTS OF ACRYLAMIDE AND ITS EPOXIDE METABOLITE GLYCIDAMIDE IN THE RAT [J].
BERGMARK, E ;
CALLEMAN, CJ ;
COSTA, LG .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1991, 111 (02) :352-363
[7]   ACRYLAMIDE NEUROPATHY - CHANGES IN THE COMPOSITION OF PROTEINS OF FAST AXONAL-TRANSPORT RESEMBLE THOSE OBSERVED IN REGENERATING AXONS [J].
BISBY, MA ;
REDSHAW, JD .
JOURNAL OF NEUROCHEMISTRY, 1987, 48 (03) :924-928
[8]   AXOPLASMIC FLOW IN AXONAL NEUROPATHIES .1. AXOPLASMIC FLOW IN CATS WITH TOXIC NEUROPATHIES [J].
BRADLEY, WG ;
WILLIAMS, MH .
BRAIN, 1973, 96 (JUN) :235-246
[9]   ACRYLAMIDE AND GLYCIDAMIDE IMPAIR NEURITE OUTGROWTH IN DIFFERENTIATING N1E.115 NEUROBLASTOMA WITHOUT DISTURBING RAPID BIDIRECTIONAL TRANSPORT OF ORGANELLES OBSERVED BY VIDEO MICROSCOPY [J].
BRAT, DJ ;
BRIMIJOIN, S .
JOURNAL OF NEUROCHEMISTRY, 1993, 60 (06) :2145-2152
[10]  
BROWN MJ, 1978, P 4 INT C NEUR DIS E, P276